Titlebook: Recent Advances of Sarcopenia and Frailty in CKD; Akihiko Kato,Eiichiro Kanda,Yoshihiko Kanno Book 2020 Springer Nature Singapore Pte Ltd.

刺耳

Homocystinuria

Pharmacological Intervention for Sarcopenia in Chronic Kidney Disease,e size, varying the range of doses during treatment, and observing other outcomes. Supplementation with ursolic acid is also an intriguing candidate to combat normal and CKD-induced sarcopenia, although further systematic and fundamental research is needed for this treatment on humans.

preeclampsia

追蹤

Anemia Management and QOL and Frailty in CKD, improvement of HRQOL with uncertain clinical significance..Further investigations are required to individualize of the patients that 11.5–13.0?g/dL Hb target is effective for clinically meaningful HRQOL improvement without increasing the risks.

Accommodation

禮節(jié)

Exercise Intervention for Kidney Transplant Recipients: Recent Progress and Remaining Issues,daily clinical practice remains unknown. Recommendation of the strength and type of exercise for Japanese transplant patients remains unclear. A tailor-made exercise prescription for the individual recipients is required.

關(guān)心

anachronistic

Camouflage

Epidemiology of Sarcopenia and Frailty in CKD,evalence of sarcopenia and frailty are substantially higher in CKD patients compared to the general population. Sarcopenia is defined according to the Asian Working Group for Sarcopenia (AWGS), while frailty according to the Japanese version of the Cardiovascular Health Study (J-CHS) in Japan. Sarco

Hamper

Molecular Mechanism of Muscle Wasting in CKD,ade into the molecular mechanisms of muscle atrophy in CKD. A persistent imbalance between protein synthesis and degradation causes a loss of muscle mass. A decrease in insulin/IGF-1-Akt-mTOR signaling and an increased ubiquitin-proteasome system (UPS) have emerged as inducers of muscle loss. During